Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Ron Bentsur M.B.A.

Market Cap

152.14 Million USD

Sector

Healthcare

Website

https://www.nuvectis.com

Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.

Read More

Overview

Value

1

Growth

20

Health

29

Management

0

Analyst Opinion

60

Total

28

All Scores Out Of 100

Best Features

  • Has a low level of debt
  • Low preportion of income is paid as dividend
  • 0

Risk Factors

  • Overvalued on cashflow basis
  • Earnings have declined recently
  • Earnings are negative
  • Poor overall financial health
  • Poor earnings and cashflow growth

Market Peers

NVCT

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

N/A

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Neutral

Share Buybacks

N/A

Dividend Yeild (TTM)

N/A

Valuation

Value Score

1

  • Estimated intrinsic-value of N/A is lower than current price ( 10.39 USD)
  • Free-cashflow-yeild of 0.14% is worse than the market average (4.7%)
  • Margin-of-safety of N/A is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 8 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

0.14%

PE/Earnings Growth

N/A

Price/Book

5.74x

Growth

Growth Score

20

  • Revenue growth has improved this yeara
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)

Revenue Growth

N/A

Earnings Growth

N/A

Cashflow Growth

N/A

Health

Health Score

29

  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

N/A

Debt/Equity

N/Ax

Current Assets/Liabilities

2.41x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

N/Ax

Management

Management Score

0

  • Has not bought shares or issued new shares in the last 5 years
  • Return-on-equity of 145085519.85% is higher than the market average (15%)
  • Return-on-capital-employed of -142022917.58% is lower than the market average (10%)

Average Buybacks/Dilution

N/A

Recent Buybacks/Dilution

15.13%

5 Year Price Volitility

N/A

Return On Assets

-239913084.35%

Return On Capital Employed

-142022917.58%

Return On Equity

145085519.85%

Return On Free Cashflow

N/A

Return On Investments

N/A

Analysts

Analyst Opinion

60

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Nuvectis Pharma, Inc.

Currency

USD

Beta

0

Vol Avg

37622

Ceo

Mr. Ron Bentsur M.B.A.

Cik

0001875558

Cusip

67080T108

Exchange

NASDAQ Capital Market

Full Time Employees

8

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2022-02-04

Address

1 Bridge Plaza

City

Fort Lee

State

NJ

Country

US

Zip

07024

Phone

201 614 3150

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies